High materiality9/10
H.C. Wainwright Reiterates Buy Rating on Inhibikase Therapeutics Inc (IKT)
Why it may matterVerify against the original reporting
buy
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
IKT received an analyst target update from H.C. Wainwright.
- Analyst target update from H.C. Wainwright; target $8; price $2.28.
Key facts
- 01
Target: $8
- 02
Posted price: $2.28
- 03
Analyst firm: H.C. Wainwright
- 04
Analyst: Raghuram Selvaraju
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.